Skip to main content

Affymetrix Back in Black for Second Quarter

Affymetrix today reported net income of $5.2 million on revenues of $68.6 million for the second quarter ending June 30, compared to a loss of $1.6 million on revenues of $71 million for the second quarter 2002 and a turnaround from its first quarter net loss of $12.7 million on revenues of $67 million.


The company attributed the gains to record instrument revenue of $15.6 million on top of revenues of $30 million from sales of its GeneChip brand arrays. Wafer sales to Perlegen Sciences accounted for $2.8 million, compared to $5.6 million for the same period a year ago.


Affymetrix reported R&D expenses of $16.6 million for the quarter, compared to $17.3 million for the year-ago quarter.


The company reported cash and cash equivalents of $37 million on June 30, compared to $68 million on Dec. 31, 2002.


The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.